Abstract

Osteocytes, cells ensconced within mineralized bone matrix, are the primary skeletal mechanosensors. Osteocytes sense mechanical cues by changes in fluid flow shear stress (FFSS) across their dendritic projections. Loading-induced reductions of osteocytic Sclerostin (encoded by Sost) expression stimulates new bone formation. However, the molecular steps linking mechanotransduction and Sost suppression remain unknown. Here, we report that class IIa histone deacetylases (HDAC4 and HDAC5) are required for loading-induced Sost suppression and bone formation. FFSS signaling drives class IIa HDAC nuclear translocation through a signaling pathway involving direct HDAC5 tyrosine 642 phosphorylation by focal adhesion kinase (FAK), a HDAC5 post-translational modification that controls its subcellular localization. Osteocyte cell adhesion supports FAK tyrosine phosphorylation, and FFSS triggers FAK dephosphorylation. Pharmacologic FAK catalytic inhibition reduces Sost mRNA expression in vitro and in vivo. These studies demonstrate a role for HDAC5 as a transducer of matrix-derived cues to regulate cell type-specific gene expression.

Osteocytes are mechanoresponsive within skeletal tissue. Here, the authors show that class IIa histone deacetylases are phosphorylated by focal adhesion kinase, suggesting that HDAC5 may propagate mechanobiological cues to regulate cell type-specific gene expression.

Details

Title
A FAK/HDAC5 signaling axis controls osteocyte mechanotransduction
Author
Sato Tadatoshi 1 ; Verma Shiv 1 ; Andrade Christian D Castro 1 ; Omeara Maureen 1 ; Campbell, Nia 1 ; Wang, Jialiang S 1 ; Cetinbas Murat 2 ; Lang, Audrey 1 ; Ausk, Brandon J 3 ; Brooks, Daniel J 4 ; Sadreyev, Ruslan I 5 ; Kronenberg, Henry M 6 ; Lagares, David 7   VIAFID ORCID Logo  ; Uda Yuhei 8   VIAFID ORCID Logo  ; Pajevic, Paola Divieti 8 ; Bouxsein, Mary L 9   VIAFID ORCID Logo  ; Gross, Ted S 3 ; Wein, Marc N 10   VIAFID ORCID Logo 

 Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, USA 
 Department of Molecular Biology and Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, USA 
 University of Washington, Department of Orthopaedics and Sports Medicine, Seattle, USA (GRID:grid.34477.33) (ISNI:0000000122986657) 
 Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, USA (GRID:grid.34477.33); Center for Advanced Orthopaedic Studies, Department of Orthopedic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA (GRID:grid.34477.33) 
 Department of Molecular Biology and Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, USA (GRID:grid.34477.33) 
 Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, USA (GRID:grid.34477.33) 
 Center for Immunology and Inflammatory Diseases, Fibrosis Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, USA (GRID:grid.34477.33) 
 Boston University, Translational Dental Medicine, Henry M. Goldman School of Dental Medicine, Boston, USA (GRID:grid.189504.1) (ISNI:0000 0004 1936 7558) 
 Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, USA (GRID:grid.189504.1); Center for Advanced Orthopaedic Studies, Department of Orthopedic Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA (GRID:grid.189504.1) 
10  Endocrine Unit, Massachusetts General Hospital, Harvard Medical School, Boston, USA (GRID:grid.34477.33); Broad Institute of Harvard and MIT, Cambridge, USA (GRID:grid.66859.34) 
Publication year
2020
Publication date
2020
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2419205756
Copyright
© The Author(s) 2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.